Credit Suisse’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-57,864
| Closed | -$250K | – | 3155 |
|
|
2023
Q3 | $250K | Sell |
57,864
-12,853
| -18% | -$71.4K | ﹤0.01% | 2983 |
|
|
2023
Q2 | $466K | Buy |
70,717
+21,355
| +43% | +$137K | ﹤0.01% | 2818 |
|
|
2023
Q1 | $335K | Buy |
49,362
+15
| +0% | +$105 | ﹤0.01% | 2950 |
|
|
2022
Q4 | $365K | Sell |
49,347
-7,977
| -14% | -$77.7K | ﹤0.01% | 2942 |
|
|
2022
Q3 | $566K | Buy |
57,324
+322
| +0.6% | +$3.4K | ﹤0.01% | 2715 |
|
|
2022
Q2 | $621K | Sell |
57,002
-3,482
| -6% | -$36.1K | ﹤0.01% | 2706 |
|
|
2022
Q1 | $684K | Sell |
60,484
-917
| -1% | -$12.1K | ﹤0.01% | 2792 |
|
|
2021
Q4 | $964K | Buy |
61,401
+224
| +0.4% | +$3.9K | ﹤0.01% | 3348 |
|
|
2021
Q3 | $1.05M | Buy |
61,177
+609
| +1% | +$10.7K | ﹤0.01% | 3298 |
|
|
2021
Q2 | $1.3M | Sell |
60,568
-6,318
| -9% | -$113K | ﹤0.01% | 3184 |
|
|
2021
Q1 | $1M | Sell |
66,886
-21,579
| -24% | -$349K | ﹤0.01% | 3321 |
|
|
2020
Q4 | $1.16M | Sell |
88,465
-18,154
| -17% | -$219K | ﹤0.01% | 3235 |
|
|
2020
Q3 | $1.03M | Sell |
106,619
-9,161
| -8% | -$97.9K | ﹤0.01% | 2905 |
|
|
2020
Q2 | $1.32M | Buy |
115,780
+77,822
| +205% | +$881K | ﹤0.01% | 2706 |
|
|
2020
Q1 | $393K | Sell |
37,958
-9,010
| -19% | -$112K | ﹤0.01% | 3255 |
|
|
2019
Q4 | $770K | Buy |
46,968
+8,991
| +24% | +$136K | ﹤0.01% | 3300 |
|
|
2019
Q3 | $504K | Sell |
37,977
-10,150
| -21% | -$141K | ﹤0.01% | 3434 |
|
|
2019
Q2 | $678K | Sell |
48,127
-23,266
| -33% | -$370K | ﹤0.01% | 3215 |
|
|
2019
Q1 | $1.31M | Buy |
71,393
+29,452
| +70% | +$671K | ﹤0.01% | 2689 |
|
|
2018
Q4 | $1.1M | Buy |
41,941
+12,269
| +41% | +$288K | ﹤0.01% | 2698 |
|
|
2018
Q3 | $680K | Sell |
29,672
-33,329
| -53% | -$680K | ﹤0.01% | 3116 |
|
|
2018
Q2 | $1.2M | Buy |
63,001
+16,243
| +35% | +$272K | ﹤0.01% | 2876 |
|
|
2018
Q1 | $788K | Buy |
46,758
+5,431
| +13% | +$90.9K | ﹤0.01% | 3121 |
|
|
2017
Q4 | $628K | Sell |
41,327
-12,349
| -23% | -$183K | ﹤0.01% | 3310 |
|
|
2017
Q3 | $961K | Buy |
53,676
+8,942
| +20% | +$150K | ﹤0.01% | 3132 |
|
|
2017
Q2 | $729K | Sell |
44,734
-169,074
| -79% | -$2.44M | ﹤0.01% | 2893 |
|
|
2017
Q1 | $2.99M | Buy |
213,808
+27,252
| +15% | +$388K | ﹤0.01% | 2038 |
|
|
2016
Q4 | $2.98M | Sell |
186,556
-12,489
| -6% | -$201K | ﹤0.01% | 2108 |
|
|
2016
Q3 | $3.31M | Buy |
199,045
+94,558
| +90% | +$1.27M | ﹤0.01% | 1981 |
|
|
2016
Q2 | $1.17M | Buy |
104,487
+20,366
| +24% | +$197K | ﹤0.01% | 2791 |
|
|
2016
Q1 | $703K | Buy |
84,121
+45,525
| +118% | +$374K | ﹤0.01% | 2997 |
|
|
2015
Q4 | $359K | Buy |
38,596
+9,378
| +32% | +$93.6K | ﹤0.01% | 3587 |
|
|
2015
Q3 | $330K | Sell |
29,218
-169,854
| -85% | -$2.08M | ﹤0.01% | 3661 |
|
|
2015
Q2 | $2.53M | Buy |
199,072
+116,275
| +140% | +$1.25M | ﹤0.01% | 2354 |
|
|
2015
Q1 | $771K | Buy |
82,797
+3,753
| +5% | +$42.4K | ﹤0.01% | 3197 |
|
|
2014
Q4 | $1.13M | Buy |
79,044
+47,570
| +151% | +$563K | ﹤0.01% | 3027 |
|
|
2014
Q3 | $327K | Buy |
31,474
+8,239
| +35% | +$108K | ﹤0.01% | 3887 |
|
|
2014
Q2 | $376K | Sell |
23,235
-58,445
| -72% | -$778K | ﹤0.01% | 3981 |
|
|
2014
Q1 | $1.33M | Buy |
81,680
+41,035
| +101% | +$583K | ﹤0.01% | 2861 |
|
|
2013
Q4 | $504K | Buy |
40,645
+11,029
| +37% | +$111K | ﹤0.01% | 3775 |
|
|
2013
Q3 | $324K | Sell |
29,616
-1,371
| -4% | -$14.6K | ﹤0.01% | 3761 |
|
|
2013
Q2 | $250K | Buy |
+30,987
| New | +$209K | ﹤0.01% | 3740 |
|
Other funds holding VNDA
Credit Suisse's VNDA Position: Q4 2023 in Review
Credit Suisse sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 57,864 shares — an estimated $250K sold.
Credit Suisse first reported a position in VNDA in Q2 2013 and held it in 42 quarters. The position peaked at $3.31M in Q3 2016. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.
- Credit Suisse reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 57,864 Vanda Pharmaceuticals shares in Q4 2023, an estimated $250K.
- Credit Suisse first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 42 quarters.
- Credit Suisse's Vanda Pharmaceuticals position peaked at $3.31M in Q3 2016.
- 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.